Is Haemonetics Undervalued Amid Recent Share Price Weakness?

Haemonetics (HAE) stock has seen recent weakness, with an 11.9% decline over 7 days, an 8.8% decline over 30 days, and a 7.5% decline year-to-date. The stock scores a 6/6 on valuation checks, suggesting it may be undervalued. The Discounted Cash Flow (DCF) model estimates an intrinsic value of $94.77 per share, a 21.9% discount to the current share price of around $74, indicating undervaluation.